GPX4 and lung carcinoma: Mechanistically, zerumbone and gefitinib can suppress lung cancer growth by inducing ferroptosis through the downregulation of GPX4, thereby enhancing the sensitivity of lung cancer cells to platinum-based chemotherapy drugs [50].